• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-07-09

  Schwartz's dissertation establishes a nuanced framework for evaluating anticancer drug responses in vitro by distinguishing proliferative arrest from cell death. This methodological advance enhances the interpretability and translational value of apoptosis-targeting agents, guiding more predictive drug development.

• Applied Azilsartan Medoxomil Monopotassium: From Bench to Mo

  2026-07-08

  Azilsartan medoxomil monopotassium (TAK 491) sets a new benchmark for high-affinity AT1 receptor antagonism, enabling robust, reproducible hypertension and cardiovascular disease research. This article unpacks experimental workflows, protocol refinements, and troubleshooting strategies with data-driven insights that maximize success with this APExBIO flagship compound.

• Reliable Cell Assays with (-)-Epinephrine (+)-bitartrate (B1

  2026-07-08

  This article offers a scenario-driven, evidence-backed guide to optimizing cell viability, proliferation, and cytotoxicity assays using (-)-Epinephrine (+)-bitartrate (SKU B1358). It addresses common laboratory challenges—such as reproducibility, protocol optimization, and product selection—by synthesizing validated literature and best practices, while highlighting how this non-selective adrenergic receptor agonist from APExBIO enables sensitive and robust experimental outcomes.

• Tivozanib (AV-951): Next-Generation VEGFR Inhibition in Onco

  2026-07-07

  Discover how Tivozanib (AV-951) redefines anti-angiogenic therapy in oncology research through unrivaled VEGFR selectivity and novel in vitro response metrics. Explore actionable, evidence-driven insights and protocol guidance for advanced cancer assays.

• miR-146a/b-5p–IRAK1–NF-κB Axis in Recurrent Spontaneous Abor

  2026-07-07

  This study uncovers a regulatory pathway involving miR-146a/b-5p, IRAK1, and the NF-κB signaling axis in unexplained recurrent spontaneous abortion (URSA). By integrating transcriptomic network analyses with functional assays, the authors demonstrate that miR-146a/b-5p modulates trophoblast function and inflammation by targeting IRAK1, offering a mechanistic basis for potential therapeutic intervention.

• Induced Bleb Structures Enhance LNP mRNA Transfection Potenc

  2026-07-06

  The referenced study demonstrates that the induction of 'bleb' structures in lipid nanoparticle (LNP) mRNA formulations—achieved through high-concentration pH 4 buffer—markedly improves transfection efficiency both in vitro and in vivo. This finding offers a formulation-based route to enhance mRNA delivery, emphasizing the significance of mRNA integrity and structural optimization in LNP design.

• E-64d: Applied Calpain Inhibition for Apoptosis and Neuropro

  2026-07-06

  E-64d enables precise, membrane-permeable inhibition of cysteine proteases—unlocking advanced workflows for dissecting apoptosis, platelet function, and neuroprotection. This guide details optimized protocols, troubleshooting insights, and the translational impact of E-64d, leveraging recent advances in death-rate analysis and regulated cell death research.

• Angiotensin I: Unraveling Mechanisms and Driving Translation

  2026-07-05

  Explore the mechanistic and translational landscape of Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu), its pivotal role in renin-angiotensin system research, and strategic guidance for leveraging this decapeptide in preclinical workflows, with insights into experimental rigor, protocol optimization, and future directions in cardiovascular and neuroendocrine modeling.

• Dacomitinib (PF-00299804): Pan-HER Inhibition and Ferroptosi

  2026-07-04

  Explore how Dacomitinib (PF-00299804) advances cancer research through potent pan-HER inhibition while intersecting with emerging insights into mitochondrial ferroptosis regulation. This article provides a deep, comparative analysis and practical guidance for translational oncology studies.

• SR-202: Advancing PPARγ Antagonism in Insulin Resistance Res

  2026-07-03

  SR-202, a highly selective PPARγ antagonist, empowers researchers to dissect the molecular basis of insulin resistance, adipogenesis, and immune-metabolic signaling with exceptional specificity. This article details best practices for applying SR-202 in experimental workflows, highlights troubleshooting strategies, and bridges recent advances in macrophage polarization and metabolic disease modeling.

• KU-55933: Potent ATM Kinase Inhibitor for DNA Damage Respons

  2026-07-03

  KU-55933 is a nanomolar-potency ATM kinase inhibitor that enables precise modulation of the DNA damage response. It selectively inhibits ATM kinase with minimal effect on related enzymes, making it a benchmark tool for cancer cell proliferation studies. This article details its mechanism, use protocols, and evidence-backed benchmarks for DNA damage response research.

• Pronase E: Powering Translational Ferroptosis Research in On

  2026-07-02

  Explore how Pronase E (Activity ≥ 7000 U/g) enables high-resolution mechanistic studies in triple-negative breast cancer and ferroptosis, bridging biochemical insight with translational impact. This article offers protocol guidance, critical appraisal of recent ferroptosis findings, and strategic considerations for molecular oncology labs.

• Homoharringtonine: Cytotoxic Alkaloid Workflows for Cancer a

  2026-07-02

  Homoharringtonine uniquely bridges cancer biology and antiviral research, enabling rapid, robust workflows for both leukemia and SARS-CoV-2 studies. This guide delivers actionable protocols, troubleshooting insight, and a direct translation of landmark findings into lab-ready experiments.

• SB 431542: Strategic Use of ALK5 Inhibition in Translational

  2026-07-01

  Explore how SB 431542, a selective ALK5 inhibitor, is reshaping TGF-β pathway research and translational immunology. This article provides mechanistic depth, strategic protocol guidance, and a forward-looking perspective on anti-tumor and maternal-fetal interface innovation.

• Toremifene and the STIM1-Ca2+ Axis: New Horizons in Prostate

  2026-07-01

  Explore how Toremifene—an advanced selective estrogen-receptor modulator—enables translational researchers to dissect emerging metastatic mechanisms in prostate cancer, particularly via the TSPAN18-STIM1-Ca2+ pathway. This article integrates mechanistic insight, protocol guidance, and strategic outlook, providing actionable intelligence for next-generation hormone-responsive cancer research.

16190 records 1/1080 page Next 12345 下5页 Last page